Prophylactic dendritic cell-based vaccines efficiently inhibit metastases in murine metastatic melanoma

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Markov, Oleg V ^a   Mironova, Nadezhda L ^a   Sennikov, Sergey V ^b   Vlassov, Valentin V ^a   Zenkova, Marina A ^a  

^a INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^b INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

1,26 BIS(1,2 DE O TETRADECYL RAC GLYCEROL) 7,11,16,20 TETRAAZAHEXACOSAN TETRAHYDROCLORIDE; DENDRITIC CELL VACCINE; LIPID; LIPOFECTAMINE; LIPOFECTAMINE 2000; LIPOSOME; PHOSPHATIDYLETHANOLAMINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR RORG; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; 1,2-DIELAIDOYLPHOSPHATIDYLETHANOLAMINE; CANCER VACCINE; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; LEWIS CARCINOMA; LUNG METASTASIS; MALE; MELANOMA B16; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIMARY TUMOR; TH17 CELL; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CHEMISTRY; DENDRITIC CELL; EXPERIMENTAL MELANOMA; GENETIC TRANSFECTION; IMMUNOLOGY; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; VACCINATION;

ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; LIPOSOMES; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; PHOSPHATIDYLETHANOLAMINES; TRANSFECTION; VACCINATION;

EID: 84943339568     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136911     Document Type: Article

References (54)

1. Aly HA. Cancer therapy and vaccination. J Immunol Methods. 2012; 382:1-23. doi:10.1016/j.jim.2012. 05.014 PMID: 22658969
2. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12: 265-77. doi:10.1038/nrc3258 PMID: 22437871
3. Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J Intern Med. 2011; 269: 64-73. doi:10.1111/j.1365-2796.2010.02317.x PMID: 21158979
4. Ahmed MS, Bae YS. Dendritic cell-based therapeutic cancer vaccines: past, present and future. Clin Exp Vaccine Res. 2014; 3:113-6. doi:10.7774/cevr.2014.3.2.113 PMID: 25003083
5. Salem ML. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy. Methods Mol. Biol. 2014; 1139: 479-503. doi:10.1007/978-1-4939-0345-0 37 PMID: 24619701
6. Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, Lee Y, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int. J. Oncol. 2012; 41: 1601-1609. doi:10.3892/ijo.2012.1626 PMID: 22971679
7. Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology. 2013; 2: e22664. doi:10.4161/onci.22664 PMID: 23482679
8. Kim SK, Yun CH, Han SH. Enhanced anti-cancer activity of human dendritic cells sensitized with gamma-irradiation-induced apoptotic colon cancer cells. Cancer Lett. 2013; 335: 278-288. doi:10.1016/j.canlet.2013.02.038 PMID: 23485725
9. Palma M, Hansson L, Choudhury A, Näsman-Glaser B, Eriksson I, Adamson L, et al. Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. Cancer Immunol. Immunother. 2012; 61: 865-879. doi:10.1007/s00262-011-1149-5 PMID: 22086161
10. Matheoud D, Baey C, Vimeux L, Tempez A, Valente M, Louche P, et al. Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model. PLoSOne. 2011; 6: e19104. doi:10.1371/journal.pone.0019104 PMID: 21552572
11. Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, et al. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology. 2012; 1: 287-297. PMID: 22737604
12. Breckpot K, Heirman C, Neyns B, Thielemans K. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J. Gene. Med. 2004; 6:1175-1288. PMID: 15468193
13. Liechtenstein T, Perez-Janices N, Bricogne C, Lanna A, Dufait I, Goyvaerts C, et al. Immune modulation by genetic modification of dendritic cells with lentiviral vectors. Virus Res. 2013; 176:1-15. doi:10.1016/j.virusres.2013.05.007 PMID: 23726846
14. Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K. mRNA-based dendritic cell vaccines. Expert Rev Vaccines. 2014; 8:1-16. doi: 10.1586/14760584.2014.957684
15. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39: 38-48. doi:10.1016/j.immuni.2013.07.004 PMID: 23890062
16. Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res. 2010; 30: 5091-7. PMID: 21187495
17. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003; 63: 2127-33. PMID: 12727829
18. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, et al. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010; 8: 89. doi:10.1186/1479-5876-8-89 PMID: 20875102
19. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, et al. Targeting CD4(+)T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 2013; 73: 19-29. doi:10.1158/0008-5472.CAN-12-1127 PMID: 23087058
20. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013; 62: 909-18. doi:10.1007/s00262-013-1396-8 PMID: 23589106
21. Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, et al. otype-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer. 2012; 12: 623. doi:10.1186/1471-2407-12-623 10.1186/1471-2407-12-623. PMID: 23270484
22. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, et al. Phase I trial of a multi-epi-tope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013; 62:125-35. doi:10.1007/s00262-012-1319-0 PMID: 22847020
23. Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, Lee Y, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol. 2012; 41: 1601-9. doi:10.3892/ijo.2012.1626 PMID: 22971679
24. Drake CG. Update on prostate cancer vaccines. Cancer J. 2011; 17: 294-9. doi:10.1097/PPO. 0b013e3182325e78 PMID: 21952278
25. Frank SA. Genetic predisposition to cancer - insights from population genetics. Nat Rev Genet. 2004; 5: 764-72. PMID: 15510167
26. Tung N. Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA. 2011; 305: 2211-20. doi:10.1001/jama.2011.678 PMID: 21558506
27. Liu T, Hossain M, Schepmoes AA, Fillmore TL, Sokoll LJ, Kronewitter SR, et al. Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. J Proteomics. 2012; 75: 4747-57. doi:10.1016/j.jprot.2012.01.035 PMID: 22846433
28. Meany DL, Sokoll LJ, Chan DW. Early detection of cancer: immunoassays for plasma tumor markers. Expert Opin Med Diagn. 2009; 3: 597-605. doi:10.1517/17530050903266830 PMID: 19966928
29. Mossoba ME, Walia JS, Rasaiah VI, Buxhoeveden N, Head R, Ying C, et al. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol Ther. 2008; 16: 607-17. doi:10.1038/sj.mt.6300390 PMID: 18180774
30. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol. 2000; 165: 5713-9. doi:10.4049/jimmunol.165.10.5713 PMID: 11067929
31. Xie J, Xiong L, Tao X, Li X, Su Y, Hou X, et al. Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma. Lung Cancer. 2010; 68: 338-45. doi:10.1016/j.lungcan.2009.07.007 PMID: 19671483
32. Yang S, Vervaert CE, Burch J Jr, Grichnik J, Seigler HF, Darrow TL. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Int J Cancer. 1999; 83: 532-40. PMID: 10508491
33. Prasad SJ, Farrand KJ, Matthews SA, Chang JH, McHugh RS, Ronchese F. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol. 2005; 174: 90-8. PMID: 15611231
34. Samadi-Foroushani M, Vahabpour R, Memarnejadian A, Namdar A, Khamisabadi M, Sadat SM, et al. Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination. Med Oncol. 2011; 28 Suppl 1: S660-6. doi:10.1007/s12032-010-9720-z PMID: 21042958
35. Hong X, Dong T, Hu J, Yi T, Li W, Zhang Z, et al. Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. Int J Colorectal Dis. 2013; 28: 25-33. doi:10.1007/s00384-012-1530-7 PMID: 22777000
36. Pandey VK, Shankar BS, Sanis KB. G1-4 A, an arabinogalactan polysaccharide from Tinosporacordifolia increases dendritic cell immunogenicity in a murine lymphoma model. Int Immunopharmacol. 2012; 14: 641-9. doi:10.1016/j.intimp.2012.09.020 PMID: 23079132
37. Mendoza L, Bubeník J, Símová J, Jandlová T, Vonka V, Mikysková R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol. 2003; 23: 243-7. doi:10.3892/ijo.23.1.243 PMID: 12792800
38. Oda Y, Suzuki R, Otake S, Nishiie N, Hirata K, Koshima R, et al. Prophylactic immunization with Bubble liposomes and ultrasound-treated dendritic cells provided a four-fold decrease in the frequency of melanoma lung metastasis. J Control Release. 2012; 160: 362-6. doi:10.1016/j.jconrel.2011.12.003 PMID: 22192573
39. Matheoud D, Perié L, Hoeffel G, Vimeux L, Parent I, Marañón C, et al. Cross-presentation by dendritic cells from live cells induces protective immune responses in vivo. Blood. 2010; 115: 4412-20. doi:10.1182/blood-2009-11-255935 PMID: 20308597
40. Markov O, Mironova NL, Maslov MA, Petukhov IA, Morozova NG, Vlassov VV, et al. Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cells and their immature offsets. J Control Release. 2012; 160: 200-10. doi:10.1016/j.jconrel.2011.11.034 PMID: 22155599
41. Kong W, Yen JH, Ganea D. Docosahexaenoic acid prevents dendritic cell maturation, inhibits antigen-specific Th1/Th17 differentiation and suppresses experimental autoimmune encephalomyelitis. Brain Behav Immun. 2011; 25: 872-82. doi:10.1016/j.bbi.2010.09.012 PMID: 20854895
42. Begum-Haque S, Sharma A, Kasper IR, Foureau DM, Mielcarz DW, Haque A, et al. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2008; 204: 58-65. doi:10.1016/j.jneuroim.2008.07.018 PMID: 18804287
43. Huck SP, Tang SC, Andrew KA, Yang J, Harper JL, Ronchese F. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+T cells against tumors. Cancer Immunol Immunother. 2008 Jan; 57(1):63-71. PMID: 17609951
44. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013; 62:1499-509. doi:10.1007/s00262-013-1453-3 PMID: 23817721
45. Flörcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Jöhrens K, et al. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. Hum Vaccin Immunother. 2013; 9:1217-27. doi:10.4161/hv. 24149 PMID: 23458999
46. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013; 258: 879-86. doi:10.1097/SLA.0b013e318292919e PMID: 23657083
47. Benencia F, Sprague L, McGinty J, Pate M, Muccioli M. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol. 2012; 2012: 425476. doi:10.1155/2012/425476 PMID: 22505809
48. Töpfer K, Kempe S, Müller N, Schmitz M, Bachmann M, Cartellieri M, et al. Tumor evasion from T cell surveillance. J Biomed Biotechnol. 2011; 2011: 918471. doi:10.1155/2011/918471 PMID: 22190859
49. Finn OJ. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res. 2014; 2: 708-13. doi:10.1158/2326-6066.CIR-14-0110 PMID: 25092812
50. Rizzo MM, Alaniz L, Mazzolini G. Ex vivo loading of autologous dendritic cells with tumor antigens. Methods Mol Biol. 2014; 1139: 41-4. doi:10.1007/978-1-4939-0345-0 5 PMID: 24619669
51. Pan K, Zhao JJ, Wang H, Li JJ, Liang XT, Sun JC, et al. Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma-derived RNA or cell lysate. Int J Biol Sci. 2010; 6: 639-48. PMID: 20975822
52. Schaft N, Dörrie J, Nettelbeck DM. (Editors Lutz MB, Romani N, Steinkasserer A). Handbook of Dendritic Cells. Biology, Diseases, and Therapies. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA; 2006, pp. 1143-71. doi: 10.1002/9783527619696.ch55
53. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol. 2003; 21: 713-58. doi:10.1146/annurev.immunol.21.120601.140942 PMID: 12500979
54. Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, et al. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer Res. 2013; 73: 3545-54. doi:10.1158/0008-5472.CAN-12-2449 PMID: 23539449